Whitepaper: Drug repurposing strategies to shorten timelines
This whitepaper explores drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
List view / Grid view
This whitepaper explores drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
Why are precision medicines important? What challenges face their development and manufacture? Where could they be in 10 years? Discover all this and more in this podcast with Janssen!
Looking at patent and publication data, researchers show the applications and potential of cell-free protein synthesis systems are growing.
Growth in the global transfection technologies market will be driven by emerging methods and the increasing prevalence of chronic diseases over the next five years.
Researchers have developed a novel platform technology, iVAX, that could enable the decentralised bioproduction of conjugate vaccines and enhance vaccination rates in developing nations.
Critically examining data management in ADC development and research.
Research comparing intensified bioprocesses to fed-batch shows high cell density perfusion significantly advances productivity while maintaining quality and costs.
Higher order protein catenation enables the development of artificial antibodies with improved binding affinity and prolonged serum half-life, shows study.
Research shows using the greatest common divisor (GCD) to define batches in continuous biomanufacturing enhances process control and raw material traceability.
Join Rey Mali and Félix Montero-Julian as they discuss the challenges facing the manufacture and QC of advanced therapy medicinal products (ATMPs) and potential solutions.
This webinar considers the fundamental importance of water system control within pharma processing and the best control and monitoring practices.
This whitepaper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods will not solve.
The Gates Biomanufacturing Facility announced a strategic agreement with Nkarta to manufacture Nkarta's investigational cell therapy NKX101.
The biopharmaceutical industry performed significantly above average in EcoAct’s Climate Reporting Performance analysis – but what steps are big pharma companies taking to improve sustainability and how much further do they need to go?
Telstar promotes innovative aseptic production solutions in a setting marked by the new GMP Annex 1.